GlaxoSmithKline (GSK)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 14.3 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 12.4 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Last ex-div: 8th May, paid: 11th Jul more... Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -7.4% | |||||||||
FINANCIAL BRIEF: For the three months ended 31 March 2013, GlaxoSmithKline plc revenues decreased 3% to L6.47B. Net income decreased 27% to L961M. Revenues reflect Pharmaceuticals segment decrease of 3% to L5.12B, Japan segment decrease of 19% to L447M, United States segment decrease of 5% to L1.7B, Europe segment decrease of 2% to L1.27B. Net income also reflects Corporate & Other Unallocated segment loss increase from L275M to L591M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Mar '13) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 2 | 3 | 13 | 6 | 5 |
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 31, 2012, the Company completed the divestment of brands in the United States and Canada to Prestige Brands Holdings. In August 2012, it acquired Human Genome Sciences. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd.
Directors: Andrew Witty (CEO) 48, Simon Dingemans (CFO) 49, Moncef Slaoui (Corp. Exec.) 53, Deirdre Connelly (Corp. Exec.) 52, Roger Connor (Corp. Exec.) , Marc Dunoyer (Corp. Exec.) , Eddie Gray (Corp. Exec.) , Shah Abbas Hussain (Corp. Exec.) 47, Jean Stephenne (Corp. Exec.) 61, Patrick Vallance (Corp. Exec.) ,
No. of Employees: 98,681 No. of Shareholders: 145,355
| Last Annual | December 31st, 2012 |
| Last Interim | March 31st, 2013 |
| Shares in Issue | 4,844,000,000 |
| Free Float | 4.91bn (101.4%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | E300 PHAR & BIO IDX, FTSE Eurofirst 100 , FTSEUROFIRST 300 , E300 ex EURO COR, FTSE Higher Yield , FTSE 350 Act , FTSE Global 100, FT350 Phar & Bio , FTSE 100 , FTSE 100 Eod Gbp , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | C8 Gsk House 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom |
| Web | http://www.gsk.com |
| Phone | +44 20 80475000 |
| Contact | David Mawdsley (Director of Investor Relations) |
| Registrar | Equiniti Limited |
| Auditors | PricewaterhouseCoopers LLP |
| Fri 5:58pm | Transaction in Own Shares |
| Fri 4:13pm | Director/PDMR Shareholding |
| Fri 2:34pm | Director/PDMR Shareholding |
| Fri 9:52am | Blocklisting Interim Review |
| Thu 4:24pm | Director/PDMR Shareholding |
| Wed 6:07pm | Director/PDMR Shareholding |
Recent ↓
